Who We Are
Neurox is a group of Harvard neurobiologists developing treatments for Alzheimer’s Disease (AD). We study brain development—how everyone’s daily activities change the way their genes are expressed, and how this affects connections of brain cells. We have successfully identified compounds that stimulate the growth of these connections in both Alzheimer's-affected and healthy brain cells, and are preparing for their further implementation.
The Problem We Are Solving
AD is an irreversible, devastating brain disease that destroys a person’s memory. There is currently no cure for AD, only temporary relief of symptoms. Currently, 35 million people worldwide suffer its effects, but with a growing population living longer than ever, that number will only increase—unless something is done.
The basis for memory loss in early AD seems likely to involve synaptic damage caused by beta amyloid. Recent evidence suggests that early AD almost solely comprises severely dysfunctional memory, and synapse loss is considered to be the best correlate of AD dementia.
In the past, efforts to combat AD focused on removing potentially harmful substances such as beta amyloid plaque and tau protein aggregates from the patient’s brain. Unfortunately, these methods have not led to effective therapies for existing cases of AD or any method to prevent its onset.
One difficult feature of AD lies in its negative effect on axons and dendrites, the interconnections (synapses) between brain cells. As more and more of these synapses wither away, the affected neurons eventually die. We have explored if promoting growth of the connections between these cells may be the key to treating AD. To this end, we developed the very first high-content drug screening system in the world—using real brain cells—to find drug compounds capable of enhancing the growth and connectivity of brain cells.Achievements So Far
We have developed a powerful, proprietary drug screening system that is unique to the industry. Using this method, we have already found several promising drug compounds that enhance neuronal growth and connectivity. During in vitro trials, some of these compounds restore the connectivity of AD-afflicted brain cells.
What Comes Next
We founded Neurox with a plan to license the technologies we invented and the lead compounds we developed while working at Harvard University. At Neurox we will test these potential drug compounds using animal models and will continue to use the drug-discovering platform to find more potential treatments.
We are actively raising start-up funding. If you are interested in learning more about our venture regarding research, investment, or collaboration opportunities, please feel free to contact us.